Trials / Completed
CompletedNCT02434484
Symbenda Post-Marketing Surveillance (PMS)
Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a PMS of Symbenda Injection (bendamustine hydrochloride) in Korean Patients. The main objective is to obtain safety information related to Symbenda treatment from clinical practice.
Conditions
Timeline
- Start date
- 2018-07-04
- Primary completion
- 2020-03-20
- Completion
- 2020-03-20
- First posted
- 2015-05-05
- Last updated
- 2021-01-26
Locations
9 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02434484. Inclusion in this directory is not an endorsement.